ALKS Fair Value Estimate
$101.41170.6% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Alkermes plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedProfile
Valuation (TTM)
Market Cap$6.25B
P/E40.90
EV—
P/B3.43
Shares Out166.65M
P/Sales4.00
Revenue$1.56B
EV/EBITDA26.47
Alkermes plc (ALKS) Valuation
ALKS Valuation Metrics
FCF$483.13M
FCF Growth Rate—
EPS Growth (CAGR)-17.58%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →ALKS Valuation & Fair Value Analysis
Alkermes plc (ALKS) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Alkermes plc is $101.41. The current stock price is $37.48, suggesting the stock is 170.6% undervalued.
The price-to-earnings (P/E) ratio is 40.90. Price-to-book ratio is 3.43. Price-to-sales ratio is 4.00. Enterprise value to EBITDA is 26.47. PEG ratio is -0.11.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Alkermes plc's intrinsic value.